title: [Effectiveness and safety of natalizumab in multiple sclerosis: data of the first five years from the TOP (Tysabri Observational Program)].
authors.forename: Simó
authors.initials: S
authors.lastname: Magdolna
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001118:Argentina; D001315:Australia; D002170:Canada; D005060:Europe; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D039441:Integrin alpha4 / Q000187:drug effects; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy; D000069442:Natalizumab; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D039441:Integrin alpha4; D000069442:Natalizumab